A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms STRENGTH
- Sponsors AstraZeneca
- 12 May 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2016 Planned End Date changed from 1 Sep 2019 to 1 Nov 2019.
- 15 Apr 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2019.